EX-99.1 2 s115861_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

MISONIX FISCAL 2019 SECOND QUARTER REVENUE

RISES 22% TO A RECORD $10.2 MILLION

 

FARMINGDALE, N.Y. (February 6, 2019) – Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today reported financial results for the fiscal 2019 second quarter ended December 31, 2018 as summarized below:

 

   Three Months Ended
December 31,
  Six Months Ended
December 31,
   2018    2017    2018    2017  
             
Revenue  $10,176,453   $8,323,845   $19,537,617   $15,604,568 
Gross Profit  $7,128,374   $5,858,019   $13,738,995   $10,961,387 
GP Percentage - product revenue   70.0%   70.4%   70.3%   70.2%
Pretax loss  $(840,333)  $(1,332,352)  $(3,451,317)  $(2,825,576)
Net loss  $(840,333)  $(6,856,774)  $(3,451,317)  $(8,068,998)
                     
EBITDA (1)  $(439,786)  $(1,021,648)  $(2,684,182)  $(2,148,284)
Adjusted EBITDA (1)  $380,909   $421,578   $(195,682)  $424,035 
                     
   December 31,
2018
   June 30,
2018
           
Long Term Debt  $   $           
Cash and cash equivalents  $10,173,286   $10,979,455           

 

(1)Definitions and disclosures regarding non-GAAP financial information including reconciliations are included on page 6 of this press release.

 

Stavros Vizirgianakis, President and Chief Executive Officer of Misonix stated, “Misonix’s financial growth momentum continued in the fiscal second quarter, reflecting the ongoing successful execution of our go-to-market strategies, including our direct sales team, which has expanded our domestic market share. Growing demand for our leading ultrasonic surgical products resulted in a 22% year-over-year rise in total fiscal second quarter revenues to a record $10.2 million, including a 23% increase in consumables revenue and a 21% gain in equipment revenue. Our ability to generate revenue growth, while maintaining a healthy gross margin of approximately 70%, is highlighted by the 22% year-over-year increase in second quarter gross profit to a record $7.1 million. We were able to maintain Misonix’s double-digit top-line growth trajectory, generating 25% year-over-year growth in total revenues through the first six months of fiscal 2019. Importantly, our financial results for the second quarter and first half of fiscal 2019 confirm the benefits of our recent investments and accelerating demand for the demonstrated clinical benefits that our ultrasonic medical devices deliver to physicians, hospitals and patients.

 

“During the second quarter, we further developed our direct commercialization team while training our international distribution partners. These initiatives will enable Misonix to further penetrate existing and new markets as we prepare for the launch of Nexus, our new ultrasonic surgical platform, which we intend to launch in the second half of fiscal 2019. In addition, we are already realizing value from the recent systems and infrastructure enhancements made to support our continued growth and expect these investments to drive additional operating efficiencies across the business in the coming quarters.

 

1

 

 

“Since unveiling Nexus at the 2018 NASS Conference, we have received overwhelmingly positive feedback from surgeons and the overall market, which provides us with added confidence for its potential to serve as a third growth engine for the Company as we benefit from cross-selling opportunities, especially through deeper penetration of current customer accounts and the expansion of our addressable markets to a broader range of procedures beyond those served by our current products. While medical professionals are the driving force behind successful outcomes, Nexus presents surgeons with a powerful tool to remove hard and soft tissue with greater control, accuracy and efficiency. By incorporating multiple modalities into one modern platform with extensive functionalities, we believe Nexus will be a requisite addition to the operating room as it delivers demonstrated clinical benefits at a compelling value proposition for hospitals and outpatient clinics.

 

“Looking ahead, we are excited about the opportunities to enhance shareholder value as we continue pursuing the Company’s next phase of growth. As we bring the next generation of ultrasonic products to market and complete our transformation to a direct commercialization platform, we remain confident in our ability to generate double-digit top-line growth and improved profitability in the second half of fiscal 2019.”

 

Sales Performance Supplemental Data

 

   For the three months ended
December 31,
   Net change  
   2018    2017    $    %  
Total            
Consumables  $7,570,395   $6,162,064   $1,408,331    22.9%
Equipment   2,606,058    2,161,781    444,277    20.6%
Total  $10,176,453   $8,323,845   $1,852,608    22.3%
                     
Domestic:                    
Consumables  $5,477,995   $4,623,545   $854,450    18.5%
Equipment   600,559    776,878    (176,319)   -22.7%
Total  $6,078,554   $5,400,423   $678,131    12.6%
                     
International:                    
Consumables  $2,092,400   $1,538,519   $553,881    36.0%
Equipment   2,005,499    1,384,903    620,596    44.8%
Total  $4,097,899   $2,923,422   $1,174,477    40.2%

 

Joe Dwyer, Chief Financial Officer, added, “Our fiscal 2019 second quarter results marked another outstanding quarter for Misonix, resulting in continued robust top-line growth, healthy margins and an improved bottom line, highlighting our successful execution across multiple fronts.

 

“During the first half of fiscal 2019, we undertook a range of initiatives to eliminate inefficiencies in our procurement and distribution, including bringing new suppliers on board and diversifying our supply chain. We also fully transitioned to a significantly more capable ERP system as well as instituted new policies to ensure optimal inventory levels and fulfillment outcomes. With these initiatives now largely behind us, we are confident in our ability to successfully and efficiently meet the added demand we expect.

 

“As we enter the second half of fiscal 2019, we remain well-positioned to continue to invest in our products and further improve our operations and our position in the market. We are confident that we have the capital flexibility we need, including $10.2 million in cash and no debt, to ensure that we adequately support our growth via both organic and inorganic growth initiatives and look forward to driving long-term value for our shareholders as we remain disciplined and focused in generating attractive rates of returns. Looking ahead to the second half of fiscal 2019, we reiterate our guidance for product revenue growth in excess of 20% for fiscal 2019, along with gross profit margins of approximately 70%.”

 

2

 

 

Fiscal Second Quarter 2019 Conference Call

Misonix will host a conference call and webcast today, Wednesday, February 6, 2019, at 4:30 p.m. ET to discuss its financial results and operations and host a question and answer session. The dial in number for the audio conference call is 888-599-8686 (domestic) or 323-994-2093 (international), conference ID 9194323. Participants may also listen to a live webcast of the call at the Company’s website through the “Events and Presentations” section under “Investor Relations” at www.misonix.com. Following its completion, a replay of the webcast will be available for 30 days on the Company’s website, www.misonix.com.

 

About Misonix, Inc.

Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets ultrasonic medical devices for the precise removal of hard and soft tissue, including bone removal, wound debridement and ultrasonic aspiration. Misonix is focused on leveraging its proprietary ultrasonic technology to become the standard of care in operating rooms and clinics around the world. Misonix’s proprietary ultrasonic medical devices are used in a growing number of medical procedures, including spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of ultrasonic surgical products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.

 

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, the impact of the pending investigation by the Department of Justice and Securities Exchange Commission, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking statements.

 

Contact:  
Joe Dwyer Joseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial Officer JCIR
Misonix, Inc. 212-835-8500 or mson@jcir.com
631-694-9555  

 

3

 

 

Misonix, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

 

    For the three months ended
December 31,
  For the six months ended
December 31,
 
    2018     2017     2018     2017  
           
Revenues Product   $10,176,453  $8,323,845  $19,537,617  $15,604,568 
Total revenue    10,176,453   8,323,845   19,537,617   15,604,568 
                   
Cost of goods sold    3,048,079   2,465,826   5,798,622   4,643,181 
Gross profit    7,128,374   5,858,019   13,738,995   10,961,387 
                   
Operating expenses:                  
Selling expenses    4,800,643   3,919,515   9,535,648   7,490,228 
General and administrative expenses    2,347,184   2,380,860   5,530,568   4,953,991 
Research and development expenses    839,219   957,204   2,143,984   1,858,478 
Total operating expenses    7,987,046   7,257,579   17,210,200   14,302,697 
Loss from operations    (858,672)  (1,399,560)  (3,471,205)  (3,341,310)
                   
Other income (expense):                  
Interest income    17,242   45   37,056   58 
Royalty income    1,105   71,550   1,105   524,521 
Other    (8)  (4,387)  (18,273)  (8,845)
Total other income    18,339   67,208   19,888   515,734 
                   
Loss from operations before income taxes    (840,333)  (1,332,352)  (3,451,317)  (2,825,576)
                   
Income tax expense       5,524,422      5,243,422 
Net loss   $(840,333) $(6,856,774) $(3,451,317) $(8,068,998)
                   
Net loss per share:                  
Basic   $(0.09) $(0.76) $(0.37) $(0.90)
Diluted   $(0.09) $(0.76) $(0.37) $(0.90)
                   
Weighted average shares - Basic    9,322,237   8,977,984   9,210,031   8,968,195 
Weighted average shares - Diluted    9,322,237   8,977,984   9,210,031   8,968,195 

 

4

 

 

Misonix, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

 

   December 31,
2018
   June 30,
2018
 
    (Unaudited)      
Assets          
Current assets:          
Cash and cash equivalents  $10,173,286   $10,979,455 
Accounts receivable, less allowance for doubtful accounts of $250,000 and $200,000, respectively   5,709,298    5,245,549 
Inventories, net   5,711,528    5,019,886 
Prepaid expenses and other current assets   601,752    611,647 
Total current assets   22,195,864    21,856,537 
           
Property, plant and equipment, net of accumulated amortization and depreciation of $9,720,862 and $9,023,235, respectively   4,473,859    4,188,378 
Patents, net of accumulated amortization of $1,132,901 and $1,063,393, respectively   763,044    757,447 
Goodwill   1,701,094    1,701,094 
Contract assets   960,000     
Intangible and other assets   451,315    517,295 
Total assets  $30,545,176   $29,020,751 
           
Liabilities and shareholders’ equity          
Current liabilities:          
Accounts payable  $3,592,287   $1,794,098 
Accrued expenses and other current liabilities   2,264,112    2,411,172 
Deferred income   5,993    13,303 
Total current liabilities   5,862,392    4,218,573 
           
Non current liabilities   401,000    401,000 
Total liabilities  $6,263,392   $4,619,573 
           
Commitments and contingencies          
           
Shareholders’ equity:          
Common stock, $.01 par value-shares authorized 40,000,000; 9,584,178 and 9,430,466 shares issued and outstanding in each period   95,842    94,305 
Additional paid-in capital   42,143,359    39,772,973 
Accumulated deficit   (17,957,417)   (15,466,100)
Total shareholders’ equity   24,281,784    24,401,178 
           
Total liabilities and shareholders’ equity  $30,545,176   $29,020,751 

 

5

 

 

Use of Non-GAAP Financial Measures

 

The Company has presented the following non-GAAP financial measures in this press release: EBITDA and Adjusted EBITDA. The Company defines EBITDA as the net income (loss) as reported under GAAP, plus depreciation and amortization expense, interest expense and income tax expense (benefit). The Company defines Adjusted EBITDA as EBITDA plus non-cash stock compensation expense and engineering costs associated with its development of Nexus, its next generation platform, which will not be a recurring cost when the project is completed in the second half of fiscal 2019.

 

We present these non-GAAP measures because we believe these measures are useful indicators of our operating performance. Our management uses these non-GAAP measures principally as a measure of our operating performance and believes that these measures are useful to investors because they are frequently used by analysts, investors and other interested parties to evaluate the operating performance of companies in our industry. We also believe that these measures are useful to our management and investors as a measure of comparative operating performance from period to period.

 

    Three Months Ended
December 31,
  Six Months Ended
December 31,
 
    2018  2017  2018  2017 
EBITDA:              
Net loss   $(840,333) $(6,856,774) $(3,451,317) $(8,068,998)
Depreciation and amortization    400,547   310,704   767,135   677,292 
Income tax benefits       5,524,422      5,243,422 
EBITDA    (439,786)  (1,021,648)  (2,684,182)  (2,148,284)
                   
Non-cash stock compensation    500,088   844,601   1,504,586   1,469,894 
Nexus next generation engineering    320,607   598,625   983,914   1,102,425 
Adjusted EBITDA   $380,909  $421,578  $(195,682) $424,035 

 

6